150 related articles for article (PubMed ID: 23715646)
1. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma.
Murphy CC; Correa AM; Ajani JA; Komaki RU; Welsh JW; Swisher SG; Hofstetter WL
J Gastrointest Surg; 2013 Aug; 17(8):1359-69. PubMed ID: 23715646
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
4. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting.
Murphy CC; Hofstetter WL; Correa AM; Ajani JA; Komaki RU; Swisher SG
Dis Esophagus; 2013; 26(7):708-15. PubMed ID: 23350713
[TBL] [Abstract][Full Text] [Related]
5. Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
Sio TT; Wilson ZC; Stauder MC; Bhatia S; Martenson JA; Quevedo JF; Schomas DA; Miller RC
Am J Clin Oncol; 2016 Oct; 39(5):448-52. PubMed ID: 24879469
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
[TBL] [Abstract][Full Text] [Related]
7. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
8. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Prognostic Significance of Extramural Venous Invasion in Patients with Locally Advanced Esophageal Cancer.
Faiz Z; Huijgen LJW; Alqethami HJ; Burgerhof JGM; Kats-Ugurlu G; Plukker JTM
Ann Surg Oncol; 2018 Jun; 25(6):1588-1597. PubMed ID: 29611027
[TBL] [Abstract][Full Text] [Related]
10. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
[TBL] [Abstract][Full Text] [Related]
11. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
[TBL] [Abstract][Full Text] [Related]
12. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
Goense L; van Rossum PSN; Xi M; Maru DM; Carter BW; Meijer GJ; Ho L; van Hillegersberg R; Hofstetter WL; Lin SH
Ann Surg Oncol; 2018 Jun; 25(6):1598-1607. PubMed ID: 29569125
[TBL] [Abstract][Full Text] [Related]
13. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer.
Ji KSY; Thomas SM; Roman SA; Czito B; Anderson KL; Frakes J; Adam MA; Sosa JA; Robinson TJ
J Gastrointest Surg; 2019 May; 23(5):885-894. PubMed ID: 30374818
[TBL] [Abstract][Full Text] [Related]
14. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
15. Disparities in survival after trimodality therapy for esophageal adenocarcinoma.
Eng OS; Nelson RA; Konstantinidis I; Chao J; Erhunmwunsee L; Raz DJ; Kim JY
Dis Esophagus; 2018 Sep; 31(9):. PubMed ID: 29534155
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer.
Cooper L; Dezube AR; De León LE; Kucukak S; Mazzola E; Dumontier C; Mamon H; Enzinger P; Jaklitsch MT; Frain LN; Wee JO
Eur J Surg Oncol; 2021 Oct; 47(10):2667-2674. PubMed ID: 33895020
[TBL] [Abstract][Full Text] [Related]
17. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
18. Nomograms for predicting overall and recurrence-free survival after trimodality therapy for esophageal adenocarcinoma.
Merritt RE; Abdel-Rasoul M; Souza DM; Kneuertz PJ
J Surg Oncol; 2021 Mar; 123(4):881-890. PubMed ID: 33333590
[TBL] [Abstract][Full Text] [Related]
19. Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma.
Alnaji RM; Du W; Gabriel E; Singla S; Attwood K; Nava H; Malhotra U; Hochwald SN; Kukar M
J Gastrointest Surg; 2016 Sep; 20(9):1541-6. PubMed ID: 27260525
[TBL] [Abstract][Full Text] [Related]
20. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
